AR021318A1 - VIRAL VECTORS WITH LATER TRANSGENIC EXPRESSION - Google Patents

VIRAL VECTORS WITH LATER TRANSGENIC EXPRESSION

Info

Publication number
AR021318A1
AR021318A1 ARP990105869A ARP990105869A AR021318A1 AR 021318 A1 AR021318 A1 AR 021318A1 AR P990105869 A ARP990105869 A AR P990105869A AR P990105869 A ARP990105869 A AR P990105869A AR 021318 A1 AR021318 A1 AR 021318A1
Authority
AR
Argentina
Prior art keywords
vectors
viral vectors
transgenic expression
provides methods
later
Prior art date
Application number
ARP990105869A
Other languages
Spanish (es)
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of AR021318A1 publication Critical patent/AR021318A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente está dirigida a virus recombinantes que contienen un transgen terapéutico ligado operativamente a un elemento regulador tardío. Los vectores dela presente son capaces de replicacion y lisis de células neoplásicas. Los vectores pueden incluir opcionalmente modificaciones para el genoma de manera deimpartir funciones adicionales terapéuticas, condicionalmente replicantes o funciones diana. La presente provee además métodos de uso de dichos vectores. Lapresente provee además métodos para preparar los vectores.This is directed to recombinant viruses that contain a therapeutic transgene operatively linked to a late regulatory element. The vectors of the present are capable of replication and lysis of neoplastic cells. Vectors may optionally include modifications to the genome in order to impart additional therapeutic functions, conditionally replicating or target functions. This also provides methods of using said vectors. The representative also provides methods for preparing the vectors.

ARP990105869A 1998-11-18 1999-11-18 VIRAL VECTORS WITH LATER TRANSGENIC EXPRESSION AR021318A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19536798A 1998-11-18 1998-11-18

Publications (1)

Publication Number Publication Date
AR021318A1 true AR021318A1 (en) 2002-07-17

Family

ID=22721149

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105869A AR021318A1 (en) 1998-11-18 1999-11-18 VIRAL VECTORS WITH LATER TRANSGENIC EXPRESSION

Country Status (6)

Country Link
EP (1) EP1131458A1 (en)
JP (1) JP2002530085A (en)
AR (1) AR021318A1 (en)
AU (1) AU2344100A (en)
CA (1) CA2351587A1 (en)
WO (1) WO2000029599A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2145300A (en) * 1998-11-18 2000-06-05 Canji, Inc. Adenoviral vectors
US20040175362A1 (en) 1999-05-12 2004-09-09 Curiel David T. Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
EP1180932B1 (en) * 1999-05-12 2012-01-11 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
GB0014820D0 (en) * 2000-06-16 2000-08-09 Medical Res Council Methods and materials relating to plasmid vectors
US6472176B2 (en) * 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
ES2385251B1 (en) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge ONCOLYTIC ADENOVIRUSES FOR THE TREATMENT OF CANCER.
KR102081567B1 (en) 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 Biomarkers and combination therapies using oncolytic virus and immunomodulation
ES2759785T3 (en) 2012-02-02 2020-05-12 Univ Texas Adenoviruses expressing heterologous oncogenic antigens
JP2016519108A (en) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド Method for using interleukin-10 for the treatment of diseases and disorders
JP7053453B2 (en) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド How to use interleukin 10 to treat diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720277B1 (en) * 1994-05-31 1996-07-12 Rhone Poulenc Rorer Sa Method of treating cancer by regulating the P53 protein.
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6113913A (en) * 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus

Also Published As

Publication number Publication date
CA2351587A1 (en) 2000-05-25
EP1131458A1 (en) 2001-09-12
AU2344100A (en) 2000-06-05
JP2002530085A (en) 2002-09-17
WO2000029599A1 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
AR021318A1 (en) VIRAL VECTORS WITH LATER TRANSGENIC EXPRESSION
ATE188740T1 (en) VIRUS PARTICLES WITH ALTERED HOST SPECTRUM
BR9609303A (en) Recombinant mva virus and its use
AU626145B2 (en) Surgical clip
ES2134346T3 (en) CYTOPATHIC VIRUSES FOR THE TREATMENT AND PROPHYLAXIS OF NEOPLASIA.
SE9003978D0 (en) DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
DK1252323T3 (en) Virus strains for the oncolytic treatment of cancer
DE69638196D1 (en) RECOMBINANT SENDAI VIRUS
DE69332831D1 (en) RECOMBINANT PIGROCK VIRUS
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
NO920774L (en) FUSION PROTEINS, THEIR PREPARATION AND USE
DK541889D0 (en) VIRUS-MODIFIED TUMOR VACCINES FOR IMMUNERY TUMOR METASTASES
KR930701610A (en) Methods of changing the cell, tissue or host orientation of microorganisms, recombinant microorganisms obtained by this method, and methods of using them in the medical and veterinary arts
ATE272713T1 (en) EHV-1 VECTORS
DK0889969T3 (en) Recombinant adenoviral for gene therapy of human tumors
BR0015740A (en) Membrane virus host range mutations and their use as vaccine substrates
BR0116328A (en) Promoter for arcelina-5 and its uses
WO2003025187A3 (en) Improvement of gene expression in vectors
HUP9902585A2 (en) Generating replicating molecules in vivo
ATE89569T1 (en) HEEMOGLOBIN WITH REDUCED VIRUS RISK AND ITS MANUFACTURE.
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
ES2163405T3 (en) RECOMBINANT VIRUSES UNDERSTANDING ARTIFICIAL PROTEOLITIC SCISION SITES.
DE69728263D1 (en) WITH MODIFIED H2-M TRANSGENIC ANIMALS
JPS63141583A (en) Transformant and production of human interferon
IT9022095A1 (en) DETACHABLE TANKS OF AIRCRAFT, HELICOPTERS, EXOREACTOR, ENDOREACTOR, CIVIL AND MILITARY WITH PROPELLANT BELOW THE FLASH POINT STABILITY, HEAT EXTRACTION.

Legal Events

Date Code Title Description
FB Suspension of granting procedure